



March 30, 2023

The Honorable Senator Charles E. Schumer  
U.S. Senate Majority Leader  
322 Hart Senate Office Building  
Washington DC 20510

Re: Request for Action on Medical Research Matter; Nonhuman Primate Model Crisis

Dear Senator Schumer:

We, the undersigned companies, organizations and institutions are actively engaged in conducting and supporting essential medical research on virtually all diseases affecting the American population. Our companies, organizations and institutions represent the majority of drug and biomedical research and development work conducted in the United States, which is critical not only to preventing the spread of infectious diseases like COVID-19, but also for the development of new innovative treatments for cancer, diabetes, and a number of other diseases currently without effective treatment options.

We are currently experiencing a crisis in which 60% of the supply of non-human primates (NHPs) critical to this work are being denied permits by the U.S. Fish and Wildlife Service. This disruption will significantly slow the U.S. biopharmaceutical pipeline, stifle scientific advancement, impair research, halt industry-wide economic growth, and deprive patients of potentially life-saving treatments. The gravity of this situation cannot be understated. A sustainable solution to this critical issue is urgently needed for all stakeholders.

Non-human primates (NHP's) have been in high demand in recent years, due in part to the focus on biologic drug pipelines as well as the need to use these models in regulatory-required drug safety testing. Because of their close genetic, physiological, and behavioral similarity to humans, NHPs are often the only relevant animal models for critical translational research.

We understand the issue at hand is the alleged illegal inclusion of wild-caught animals with captive bred animals from Cambodia and agree with the long-term goal of suppliers needing to provide accurate descriptions of all legally imported animals. We are asking that our government work with us in finding both short-term and long-term solutions to this crisis such that the pipeline for lifesaving medications will continue without interruption.

We are committed to convening conversations and sharing our knowledge, expertise, and insights with any and all public and private sector stakeholders in order to develop and facilitate the implementation of solutions. Please reach out to Matthew Bailey, President of the [National Association for Biomedical Research](http://www.nabr.org), or Brandon Morton, Director of Government Affairs at 202-857-0540 or [bmorton@nabr.org](mailto:bmorton@nabr.org). We look forward to partnering with the U.S. government to quickly secure the U.S. supply chain and find long-term solutions for nonhuman primate resource needs.

Sincerely,

Altasciences  
American Association of Immunologists (AAI)  
American College of Laboratory Animal Medicine (ACLAM)  
American College of Neuropsychopharmacology (ACNP)  
American College of Veterinary Pathologists (ACVP)  
American Physiological Society (APS)  
American Society for Pharmacology and Experimental Therapeutics (ASPET)  
American Society of Laboratory Animal Practitioners (ASLAP)  
American Society of Transplant Surgeons  
American Society of Transplantation  
American Veterinary Medical Association (AVMA)  
Americans for Medical Progress  
Association for Research in Vision and Ophthalmology (ARVO)  
Attralus  
BioImpact Capital  
BIOQUAL, Inc.  
Biotechnology Innovation Organization (BIO)  
California Biomedical Research Association (CBRA)  
Charles River Laboratories  
Context Therapeutics  
Emory National Primate Research Center  
Federation of American Societies for Experimental Biology (FASEB)  
Gemini Bioscience Resourcing  
Inotiv  
Institutional Officials Consortium (IOC)  
International Association of Colleges of Laboratory Animal Medicine (IACLAM)  
Labcorp  
Massachusetts Society for Medical Research (MSMR)  
Missouri Biotechnology Association (MOBIO)  
MPM Capital  
National Association for Biomedical Research (NABR)  
Northern Biomedical Research  
Oregon National Primate Research Center  
Orna Therapeutics  
ReNAgade Therapeutics  
Society for Neuroscience  
Society for the Neural Control of Movement  
Society of Toxicologic Pathology (STP)  
Texas Biomedical Research Institute  
Texas Society for Biomedical Research (TSBR)  
Tulane National Primate Research Center  
Vigil Neuroscience  
Virscio, Inc.  
Washington National Primate Research Center  
Wisconsin National Primate Research Center